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We recently found evidence for anatomic and physical linkages between the astroglial
Na+-dependent glutamate transporters (GLT-1/EAAT2 and GLAST/EAAT1) and mitochon-
dria. In these same studies, we found that the glutamate dehydrogenase (GDH)
inhibitor, epigallocatechin-monogallate (EGCG), inhibits both glutamate oxidation and Na+-
dependent glutamate uptake in astrocytes. In the present study, we extend this finding by
exploring the effects of EGCG on Na+-dependent L-[3H]-glutamate (Glu) uptake in crude
membranes (P2) prepared from rat brain cortex. In this preparation, uptake is almost
exclusively mediated by GLT-1. EGCG inhibited L-[3H]-Glu uptake in cortical membranes
with an IC50 value of 230µM. We also studied the effects of two additional inhibitors
of GDH, hexachlorophene (HCP) and bithionol (BTH). Both of these compounds also
caused concentration-dependent inhibition of glutamate uptake in cortical membranes.
Pre-incubating with HCP for up to 15 min had no greater effect than that observed with no
pre-incubation, showing that the effects occur rapidly. HCP decreased the Vmax for gluta-
mate uptake without changing the Km, consistent with a non-competitive mechanism of
action. EGCG, HCP, and BTH also inhibited Na+-dependent transport of D-[3H]-aspartate
(Asp), a non-metabolizable transporter substrate, and [3H]-γ-aminobutyric acid (GABA). In
contrast to the forebrain, glutamate uptake in crude cerebellar membranes (P2) is likely
mediated by GLAST (EAAT1). Therefore, the effects of these compounds were examined
in cerebellar membranes. In this region, none of these compounds had any effect on
uptake of either L-[3H]-Glu or D-[3H]-Asp, but they all inhibited [3H]-GABA uptake. Together
these studies suggest that GDH is preferentially required for glutamate uptake in forebrain
as compared to cerebellum, and GDH may be required for GABA uptake as well. They
also provide further evidence for a functional linkage between glutamate transport and
mitochondria.
Keywords: glutamate, GLT-1, EAAT2, GLAST, GABA, glutamate dehydrogenase, sodium-dependent uptake,
epigallocatechin-monogallate
INTRODUCTION
Glutamate is the predominant excitatory neurotransmitter in the
mammalian CNS and mediates the vast majority of cell-to-cell
communication in the brain [for review, see (1)]. In addition to
being required for millisecond cell-to-cell communication, plastic-
ity of excitatory synaptic transmission likely underlies learning and
memory [for reviews, see (1–3)]. Aberrant glutamatergic transmis-
sion has been implicated in a wide variety of neurodevelopmental,
neurologic, and psychiatric conditions [for review, see (3)]. For
example, an accumulation of glutamate in the extracellular space
and the consequent excessive activation of glutamate receptors
likely contributes to the cell death that is observed after acute
insults to the nervous system, such as stroke and head trauma [for
review, see (2)].
Extracellular glutamate is cleared by Na+-dependent glutamate
transport systems [for reviews, see (4–6)]. In mammals, there are
five Na+-dependent glutamate transporter gene products; these
are called excitatory amino acid transporters (EAAT1-5). EAAT1
(also called GLAST) is found on glia; expression is enriched
in cerebellum but also found throughout forebrain (7). EAAT2
(also called GLT-1) is essentially restricted to astroglia with mod-
est expression by a subset of neurons in hippocampus (7, 8).
Results from several different types of studies strongly suggest
that GLT-1 and GLAST mediate the bulk of glutamate uptake
in the mammalian brain [(9); for review, see (10)]. This clear-
ance into astroglia differentiates glutamate from most of the other
classical neurotransmitters that are directly recycled back into
the presynaptic nerve terminal [for reviews, see (11, 12)]. These
transporters co-transport three Na+ ions and one H+ with glu-
tamate in the inward direction; the cycle is completed with the
counter-transport one K+ ion (13). With this stoichiometry, these
transporters are capable of generating up to a one million-fold
concentration gradient of glutamate across the plasma membrane
[for review, see (14)].
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The astroglial transporters, GLT-1 and GLAST, are enriched
on fine astroglial processes near synapses in vivo (15, 16). As
might be expected, recent studies suggest that these transporters
co-compartmentalize with the enzymes/organelles that would be
required to efficiently fuel transport in these spatially restricted
domains (17). For example, GLT-1 or GLAST co-localize with
and physically/functionally interact with the Na+/K+ATPase (18).
Recently we showed that GLT-1 is part of a co-immunoprecipitable
complex with the Na+/K+-ATPase, most of the glycolytic enzymes,
and a subset of mitochondrial proteins (17). We also demonstrated
significant co-localization of GLT-1 with a mitochondrial protein
in vivo and anatomic overlap of mitochondria with GLT-1 in indi-
vidual astrocytes in organotypic slice cultures. In a subsequent
study, we documented similar interactions and anatomic overlap
between GLAST and mitochondrial proteins (19). In this later
study, we measured the percentage of glutamate that is oxidized
in astrocytes. We also examined the effect of an inhibitor of gluta-
mate dehydrogenase (GDH), a mitochondrial enzyme that could
contribute to glutamate oxidation, on glutamate uptake and found
that it inhibited uptake in astrocytes (19). This effect was not char-
acterized beyond testing of a single concentration of one inhibitor
in astrocytes that only express GLAST. In the present study, we
characterized the potential effects of inhibitors of GDH on uptake
in crude rat brain membranes (P2).
MATERIALS AND METHODS
MATERIALS
Adult male Sprague-Dawley rats were obtained from Charles
River (Wilmington, MA, USA). All protocols were reviewed and
approved by the Institutional Animal Care and Use Committee of
the Children’s Hospital of Philadelphia (Philadelphia, PA, USA).
l-[3H]Glu (40–80 Ci/mmol), d-[3H]Asp (10–25 Ci/mmol), and
γ-amino[3H]butyric acid ([3H]GABA; 70–100 Ci/mmol) were
obtained from PerkinElmer (Waltham, MA, USA). The specific
activity of all ligands was diluted with non-radioactive l-Glu, d-
Asp, or GABA, respectively (Sigma-Aldrich Co., St. Louis, MO,
USA). (−)-Epigallocatechin-monogallate (EGCG; ≥95%, from
green tea), hexachlorophene (HCP), bithionol (BTH), Hepes,
KCl, CaCl2, and K2HPO4 were obtained from Sigma-Aldrich
Co. (St. Louis, MO, USA). Tris base, Tris HCl, NaCl, MgCl2,
dextrose, and sucrose were obtained from Fisher Scientific (Pitts-
burgh, PA, USA). Tween-20 was obtained from Bio-Rad (Hercules,
CA, USA).
MEMBRANE PREPARATIONS
Crude membranes (P2) were prepared from cortex and cerebel-
lum as previously described (20). The preparation is commonly
referred to as “crude synaptosomal membranes.” In the current
paper, we refer to this preparation as crude membranes (P2) to
avoid giving the impression that it contains strictly neuronal ele-
ments. Cortex or cerebellum was dissected on a metal plate cooled
to 4°C. All subsequent steps were performed at 4°C. The tissue
was homogenized in 20 volumes (wet weight of tissue) of ice-
cold 0.32 M sucrose using a Dounce Teflon/glass homogenizer at
400 rpm for seven strokes (tissue homogenate) and centrifuged at
800× g for 10 min. The supernatant (S1) was then centrifuged
at 20,000× g for 20 min. In a subset of experiments, the resul-
tant supernatant was collected (S2). The resultant pellet (P2) was
resuspended in 40 vols. of sucrose (0.32 M) by vortexing and cen-
trifuged at 20,000× g for 20 min. This washed crude membrane
pellet (P2) was resuspended by vortexing in 50 vols. of sucrose
(0.32 M) and homogenized (two strokes at 400 rpm). This resulted
in a suspension of approximately 30µg of protein per 50µl as
determined by the Pierce BCA (bicinchoninic acid) protein assay
(Thermo Scientific, Rockford, IL, USA).
WESTERN BLOT ANALYSES
The subcellular fractions were mixed with equal volumes of
Laemmli sample buffer. Dual color molecular weight marker (Bio-
Rad) and 3 or 10µg of protein from each fraction were resolved on
10% SDS-polyacrylamide gels, and transferred to immobilon FL
polyvinylidene fluoride (PVDF) membranes (Millipore, Bedford,
MA, USA) as described previously (17, 19). The PVDF mem-
branes were blocked in TBS-T (50 mM Tris, pH 8.0, 150 mM
NaCl, 0.1% Tween-20) containing 5% non-fat dry milk for 1 h
at 25°C. The membranes were then probed with the appropri-
ate antibody overnight at 4°C: rabbit anti-GLT-1 (1:5,000; Dr.
Rothstein), mouse anti-GLAST (1:50; Miltenyi Biotec, Auburn,
CA, USA), mouse anti-N -methyl-d-aspartate (NMDA) recep-
tor subunit 1 (NR1; 1:500; BD Biosciences, San Jose, CA, USA),
rat anti-glial fibrillary acidic protein (GFAP; 1:500; Dr. Lee), or
goat anti-neurofilament light polypeptide (NF-L; 1:250; Santa
Cruz Biotechnology, Santa Cruz, CA, USA). The membranes
were then washed with TBS-T containing 1% milk and incu-
bated with the appropriate fluorescently conjugated anti-mouse,
anti-rabbit, anti-goat, or anti-rat antibodies (1:10,000; LiCor Bio-
sciences, Lincoln, NE, USA). Blots were scanned using an Odyssey
Infrared Imager (LiCor Biosciences). The yield was calculated
as the percentage of total immunoreactivity found in a particu-
lar fraction divided by the total immunoreactivity found in the
tissue homogenate. The enrichment was calculated as the total
immunoreactivity found in a particular fraction divided by the
total amount of protein found in the fraction; this was nor-
malized to the tissue homogenate. Therefore a number greater
than 1 reflects relative enrichment in a fraction compared to
homogenate.
TRANSPORT ASSAYS
Sodium-dependent transport of l-[3H]Glu, d-[3H]Asp, and
[3H]GABA was measured as previously described (20). Duplicate
assays were performed in a final volume of 0.5 ml containing Tris
base (5 mM), HEPES (10 mM), NaCl (140 mM), KCl (2.5 mM),
CaCl2 (1.2 mM), MgCl2 (1.2 mM), K2HPO4 (1.2 mM), dextrose
(10 mM), and substrate in the absence or presence of inhibitors
(pH= 7.2). In parallel assays, the uptake was measured in the
absence of sodium with the substitution of equimolar amounts
of choline chloride for NaCl. As HCP and BTH are not readily
soluble in aqueous solutions, they were first dissolved in ethanol
(HCP) or dimethyl sulfoxide (BTH) as 10 mM stocks. These stocks
were diluted such that the same concentration of solvent (0.1%
final concentration) was added to each assay; this meant that the
highest concentrations of HCP or BTH used in these assays were
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10µM. In all experiments, 0.1% solvent (ethanol or dimethyl sul-
foxide) was added to control assays and this concentration had no
effect on uptake (data not shown, n= 3). EGCG was prepared and
diluted in uptake buffer immediately before measuring uptake.
All components excluding the crude membranes were combined
into 12 mm× 75 mm glass tubes and equilibrated to 37°C. The
assay was initiated with the addition of P2 membranes (50µl) and
stopped with 2 ml of ice-cold (4°C) choline-containing buffer after
3 min. For analyses of the effects of pre-incubation with HCP, the
assay was initiated with the addition of radioactive substrate to
the crude membranes (P2) incubated with HCP. After the addi-
tion of cold choline-containing buffer, the assays were filtered onto
pre-wetted glass filter paper (FP-100; Brandel, Gaithersburg, MD,
USA) using a cell harvester (Brandel, Gaithersburg, MD, USA). Fil-
ters were rinsed three times with 2 ml of cold choline-containing
buffer. The radioactivity trapped in the membranes was solu-
bilized with 5 ml of Cytoscint ES (MP Biomedicals, Solon, OH,
USA) and measured using scintillation spectrometry (Beckman-
Coulter Instruments, LS 6500). Sodium-dependent uptake was
determined by subtracting the signal in the choline-containing
buffer from the signal in the sodium-containing buffer. The total
concentration of substrate (radioactive and non-radioactive) was
0.5µM unless otherwise indicated. The Na+-independent signal
observed was less than 5% of the total uptake in the presence of
sodium.
DATA ANALYSIS
All values reported are the mean± SEM of at least three inde-
pendent experiments that were performed on different days.
Concentration-response curves were fit to one-site and two-site
competition curves, and these fits were compared by F-test using
Prism 5.0 (GraphPad Software Inc., La Jolla, CA, USA). The top
of the curves were constrained to 100% (no inhibition), and for
all three compounds, the maximal predicted inhibition from the
curve fits was essentially 100% (complete inhibition). Kinetic
analyses of glutamate transport performed in the absence and
presence of HCP were fit by linear regression as Eadie–Hofstee
plots.Km andVmax values were compared using one-way ANOVA
with a Bonferroni post hoc test using InStat (GraphPad Software
Inc., La Jolla, CA, USA). The data for l-[3H]Glu, d-[3H]Asp,
and [3H]GABA uptake in cortex and cerebellum was analyzed
using one-way ANOVA with a Bonferroni post hoc test using
InStat.
RESULTS
We recently found that EGCG, a compound extracted from green
tea that inhibits GDH (21), blocks Na+-dependent glutamate
uptake in astrocytes. EGCG was only tested at a single concentra-
tion (1 mM) using a single concentration of glutamate (19). The
goal of the present study was to determine if inhibition of GDH
might inhibit Na+-dependent glutamate transport in membrane
preparations from brain. As astrocytes in culture express GLAST
and not GLT-1 (22, 23), we used crude membranes (P2) from cor-
tex to further explore this effect. Genetic deletion of GLT-1 from
mice essentially eliminates uptake from crude cortical membrane
preparations (P2), and the pharmacology of glutamate uptake
in this preparation parallels that observed for GLT-1 (9, 20, 24).
Although this is classically considered a subcellular fraction that
contains nerve terminals, it also contains substantial amounts of
astroglial elements (25, 26). We analyzed the subcellular distrib-
utions of two different glial glutamate transporters [GLT-1 and
GLAST; (15, 16)], a neuronal receptor [the NR1 subunit of the
NMDA receptor; (1)], a glial cytoskeletal protein (GFAP), and a
neuronal cytoskeletal protein [NF-L; (27); see Figure 1; Table 1].
The yield of both glutamate transporters was about 40% in the
cortical P2 fraction and about 60% in the cerebellar P2 fraction,
while the yield of NR1 was about 75% in the cortical P2 fraction
and only about 40% in the cerebellar P2 fraction. The yields of
both cytoskeletal proteins were 10% or less in both the cerebellar
and cortical P2 fractions. Together these studies show that the P2
fractions contain glial and neuronal membrane proteins consistent
with the earlier studies (25, 26).
In the first set of experiments, the effects of increasing con-
centrations of EGCG on Na+-dependent uptake were examined
(Figure 2A). The effects of EGCG were concentration-dependent
and inhibited uptake with an IC50 value of 234µM. The maxi-
mal inhibition observed was 83% at 1 mM; higher concentrations
were not tested because of solubility concerns. EGCG inhibits puri-
fied GDH with an IC50 value of ∼0.5µM (21, 28), but EGCG is
relatively hydrophilic and has limited stability in solution (29).
Several other inhibitors of GDH were recently identified in a
high-throughput screen (28). We chose two additional inhibitors
of GDH to reduce the likelihood that effects of EGCG on gluta-
mate uptake might be attributed to a non-specific interaction with
a target other than GDH. All three of these compounds interact
with different sites on GDH (30). The first compound examined,
hexachlorophene (HCP), caused a concentration-dependent inhi-
bition of Na+-dependent glutamate uptake (Figure 2B). When
these data were fit to a single site, the IC50 value was 3.9µM,
FIGURE 1 | Analyses of neuronal and astroglial proteins in tissue
homogenate (TH) and various subcellular fractions as described in
Section “Materials and Methods.” To ensure that signal was in the linear
range, 3µg of protein from each fraction were used for the analyses of
GLT-1 or GLAST and 10µg of protein were for the analyses of the other
proteins (NR1 subunit of the NMDA receptor, NR1; GFAP, and NF-L). The
western blots shown are all from one animal; these analyses have been
reproduced in three additional animals (seeTable 1 for data analyses).
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Table 1 | Analyses of neuronal and astroglial proteins in tissue homogenate (TH) and various subcellular fractionations as described in Section
“Materials and Methods.”
TH S1 S2 P2
Enrichment Yield Enrichment Yield Enrichment Yield Enrichment Yield
Cortex
GLT-1 1.0 100 1.1±0.2 93±20 0.44±0.06 17±2 1.2±0.4 39±13
GLAST 1.0 100 1.4±0.3 112±23 0.41±0.07 15±3 1.2±0.4 39±12
NR1 1.0 100 1.3±0.2 107±20 0.14±0.005 5.2±0.1 2.3±0.4 74±14
GFAP 1.0 100 0.41±0.08 34±7 0.5±0.1 19±4 0.26±0.07 8±2
NF-L 1.0 100 0.42±0.09 34±7 0.23±0.04 9±1 0.3±0.1 10±3
Cerebellum
GLT-1 1.0 100 1.3±0.09 100±5 0.4±0.3 13±8 2.7±0.7 67±20
GLAST 1.0 100 1.4±0.05 108±2 0.7±0.1 22±4 2.4±0.6 59±17
NR1 1.0 100 0.5±0.2 36±14 0.4±0.3 14±10 1.2±0.1 37±9
GFAP 1.0 100 0.37±0.05 28±4 0.57±0.08 19±2 0.18±0.02 4.4±0.7
NF-L 1.0 100 0.36±0.08 27±7 0.7±0.2 24±6 0.09±0.02 2.1±0.3
Enrichment and yield are normalized to the levels of the tissue homogenate as described in Section “Materials and Methods.” Data are the mean±SEM of at least
three independent measurements.
but the inhibition data were best fit to two sites with IC50 val-
ues of 30 nM and 14µM. The maximal inhibition observed was
70% at 10µM, and higher concentrations were not tested to avoid
effects of solvent on uptake. The reported IC50 value for inhi-
bition of GDH is 1.7µM (28). We also examined the effects of
bithionol (BTH), which caused a concentration-dependent inhi-
bition of Na+-dependent glutamate transport activity in crude
cortical membranes (P2; Figure 2C). The IC50 value was 4.1µM
when the data were fit to a single site, but the inhibition data were
best fit to two sites with IC50 values of 84 nM and 26µM. The
maximal inhibition observed was 60% at 10µM, and higher con-
centrations were not tested to avoid effects of solvent on uptake.
The reported IC50 value for inhibition of GDH is 5.5µM (28).
Together, these studies show that three different inhibitors of GDH
also inhibit Na+-dependent glutamate uptake in crude cortical
membranes (P2).
One might expect that the effects of inhibition of GDH would
increase with pre-incubation. To address this possibility, crude
cortical membranes (P2) were pre-incubated with 6.0µM HCP
for up to 15 min prior to initiation of uptake by the addition
of l-[3H]Glu. Somewhat surprisingly, the amount of inhibition
observed with pre-incubations of 1, 3, 5, 10, and 15 min was not
significantly different than that observed with no pre-incubation
(Figure 3). In these experiments, the crude membranes (P2) were
warmed to 37°C for the same amount of time, regardless of the
length of the pre-incubation with HCP, to ensure the effects seen
were independent of the increased time that the crude mem-
branes (P2) were warmed to 37°C. This shows that the effects
of HCP on glutamate uptake are very rapid and essentially instan-
taneous in this experimental paradigm where uptake is measured
for 3 min.
To further characterize the mechanism of action, we exam-
ined the effects of HCP on the concentration-dependence for
l-[3H]-Glu uptake. As was previously observed by us and others
[for review, see (31)], the Km for l-[3H]-Glu uptake was ∼5µM
and the Vmax was ∼1.2 nmol/mg/min. HCP had no effect on the
Km value and decreased the Vmax for l-[3H]-glutamate uptake
(Figure 4). These data are consistent with a non-competitive
mechanism of inhibition of glutamate uptake.
Na+-dependent glutamate uptake into crude cerebellar mem-
branes (P2) displays a dramatically different pharmacology from
that observed in crude cortical membranes [P2; (20, 32)]. In
fact, the pharmacology of transport in crude cerebellar mem-
branes (P2) is consistent with that of GLAST (24). To deter-
mine if the effects of inhibition of GDH are selective for these
two different transport activities, we compared the effects of
HCP, EGCG, and BTH on Na+-dependent glutamate uptake in
crude membranes (P2) prepared from cortex and cerebellum.
None of the GDH inhibitors had any effect on Na+-dependent
uptake in crude membranes (P2) prepared from cerebellum
(Figure 5A).
d-Aspartate is transported by the Na+-dependent glutamate
transporters (5), but is not a substrate for GDH (33). To deter-
mine if the effects of the GDH inhibitors might be related to
direct metabolism of the glutamate that moves through the trans-
porter during uptake, we examined the effects of the three different
GDH inhibitors on d-[3H]-Asp uptake in crude membranes (P2)
prepared from cortex and cerebellum. As was observed with l-
[3H]-Glu transport, all three compounds inhibited d-[3H]-Asp
uptake in crude cortical membranes (P2), and no effects were
observed in cerebellar membranes (P2; Figure 5B).
The inhibitory neurotransmitter,γ-aminobutyric acid (GABA),
is also cleared by Na+-dependent transport systems. The role of
GDH in GABA metabolism is unclear, but it may play a role in
the deamination of glutamate formed from the transamination of
GABA by GABA-transaminase, also found in mitochondria [for
discussions, see (34, 35)]. Therefore, the effects of the three dif-
ferent GDH inhibitors on Na+-dependent [3H]-GABA transport
were examined in crude membranes (P2) prepared from cortex
and cerebellum. As was observed with l-[3H]-Glu or d-[3H]-Asp,
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FIGURE 2 | Concentration-dependence of the effects of GDH inhibitors
on of Na+-dependent L-[3H]-glutamate transport into crude membranes
(P2) prepared from cortex. Transport of L-[3H]-glutamate (0.5µM) was
measured in the absence or presence of increasing concentrations of
inhibitors, as described in Section “Materials and Methods.” The percent of
control represents the velocity of transport measured in the presence of
inhibitor divided by that observed in the absence of inhibitor multiplied by
100. (A) Inhibition by EGCG was fit to a one-site competition model with an
IC50 value of 234µM. (B) Inhibition by HCP was fit to a two-site competition
model. The IC50 value for the high affinity component was 30 nM, and the
IC50 value for the lower affinity component was 14µM. Based on this fit,
33% of the sites were high affinity and 67% were of lower affinity.
(C) Inhibition by BTH was fit to a two-site competition model with an IC50
for fraction 1 (42%) of 84 nM and an IC50 for fraction 2 (58%) of 26µM. Data
are the mean±SEM of at least three independent measurements (except
for incubation of 1µM BTH, of which there were only two observations).
all three GDH inhibitors reduced Na+-dependent [3H]-GABA
transport in cortical membranes (P2; Figure 5C). However, in con-
trast to the lack of inhibition observed with l-[3H]-Glu or d-[3H]-
Asp, all three compounds also inhibited [3H]-GABA transport in
crude cerebellar membranes (P2).
FIGURE 3 | Effects of pre-incubation with HCP (6µM) on
Na+-dependent L-[3H]-glutamate transport into crude membranes (P2)
prepared from cortex. HCP (or vehicle) was added to crude membranes
(P2) at 37°C at 1, 3, 5, 10, or 15 min prior to the initiation of transport with
the addition of L-[3H]-glutamate, or simultaneously with L-[3H]-glutamate
(time=0 min). Percent of control represents the velocity of transport in the
presence of inhibitor divided by that observed in the absence of inhibitor
multiplied by 100. Data are the mean±SEM of at least three independent
measurements.
FIGURE 4 | Eadie–Hofstee plot of the concentration-dependence of
L-[3H]-glutamate transport in crude membranes (P2) prepared from
cortex with no treatment (control; circle), 0.1µM HCP (square), or
6.0µM HCP (triangle). Uptake was determined as described in Section
“Materials and Methods.” Data presented are from a single experiment
that has been repeated in four independent experiments with similar
results. The Km values for transport were 5.7±0.3µM in vehicle control,
5.4± 0.4µM in the presence of 0.1µM HCP, and 4.2±1.0µM in the
presence of 6.0µM HCP. The V max values for transport were 1.6±0.4
(nmol/mg protein/min) for vehicle control, 1.2±0.4 in the presence of
0.1µM HCP, and 0.7±0.1 in the presence of 6.0µM HCP. The Km or V max
values were normalized to vehicle controls for each experiment (set to
100%) and compared to those observed in the presence of HCP. HCP had
no significant effect on Km value, but significantly reduced the V max value at
either 0.1µM (p<0.01) or 6µM (p<0.001).
DISCUSSION
In a recent study, we obtained preliminary evidence that inhibition
of GDH might lead to inhibition of Na+-dependent glutamate
uptake (19). In the present study, we observed concentration-
dependent inhibition of Na+-dependent glutamate uptake in
crude membranes (P2) prepared from cortical tissue using three
www.frontiersin.org September 2013 | Volume 4 | Article 123 | 5
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FIGURE 5 | Effects of EGCG (300µM), HCP (6µM), or BTH (3µM) on
Na+-dependent transport of L-glutamate (A), D-aspartate (B), or GABA
(C) measured in crude membranes (P2) prepared from cortex (open
bars) or cerebellum (shaded bars). Transport of all three substrates in
both brain regions was measured in parallel experiments with different
vehicle controls as described in the Section “Materials and Methods.” Data
are the mean±SEM from at least three independent experiments. Data
were compared to vehicle controls by ANOVA. *Indicates a p<0.05, **
indicates a p<0.01, and *** indicates a p<0.001.
different inhibitors of GDH. The effects of one of these inhibitors,
HCP, were studied further. As pre-incubation did not increase the
effects of HCP, inhibition occurs relatively rapidly (within sec-
onds to minutes). HCP had no effect on Km for glutamate uptake,
but reduced Vmax, consistent with a non-competitive mechanism
of action. All three compounds also inhibited Na+-dependent d-
[3H]-Asp and [3H]-GABA to a similar extent in crude cortical
membranes (P2). However, in crude membranes (P2) prepared
from cerebellum, these compounds did not affect Na+-dependent
l-[3H]-Glu or d-[3H]-Asp, but did inhibit [3H]-GABA transport.
The fact that three different inhibitors of GDH also block Na+-
dependent glutamate and GABA uptake suggests that the observed
inhibition is likely to be due to an effect on GDH. The potencies
of HCP or BTH for inhibition of glutamate uptake are similar
to those observed for inhibition of GDH (all in the micromo-
lar range – see Results). One concern is that the concentration
of EGCG required to inhibit transport is approximately 500-fold
higher than that required to inhibit GDH; one major difference is
that the analyses of GDH were conducted with purified enzyme
(21). Others have shown that the EGCG is not particularly stable
in solution, is subject to active efflux from some cellular systems by
ABC cassette proteins, and may be poorly absorbed across mem-
branes (29, 36). Therefore, it is possible that this difference in
potency simply reflects the fact that glutamate uptake was mea-
sured in an intact system. Based on analyses of crystal structures
of GDH, HCP and BTH bind to distinct locations in the interior
of the GDH hexamer (30). Based on analyses with epicatechin 3-
monogallate (an EGCG analog), it seems that EGCG likely binds
to the ADP-activation site, located by the pivot helix of GDH (37).
We also considered the possibility that these compounds might
block glutamate uptake through a direct interaction with GLT-1,
but do not think this is likely for two different reasons. First, the
fact that three different inhibitors have the same effect on uptake
makes this a less likely explanation. Second, all three inhibitors
block sodium-dependent GABA uptake as well, which is medi-
ated by a completely distinct family of transporters that share no
homology with the glutamate transporters [for review, see (38)].
Therefore, we suggest that the simplest explanation for the present
results is that inhibition of GDH rapidly inhibits Na+-dependent
glutamate or GABA uptake.
In the present study, we found that inhibition of GDH had no
effect on l-glutamate or d-aspartate transport in crude cerebellar
membranes (P2) where GLAST likely mediates uptake (20, 24, 32).
Yet, we previously found that EGCG inhibits glutamate uptake in
astrocyte cultures (19) where uptake is also mediated by GLAST
(22, 23, 39). These measures of transport were conducted in iden-
tical buffers; this suggests that the differential effects cannot be
attributed to the utilization of different exogenous metabolites to
generate ATP. Coupling of GDH to transport may vary depend-
ing on the maturation of the system; astrocytes in culture are
polygonal, not stellate shaped as is observed in vivo, and do not
express GLT-1 consistent with an immature phenotype (22, 23).
While maturation may explain the difference between astrocytes
in culture and crude cerebellar membranes (P2), GDH has been
recently deleted from the CNS tissues in mice (40) and also been
knocked down in astrocytes in culture (41). Interestingly, the mice
with the CNS specific deletion of GDH display no overt behavioral
phenotype, and one would predict a seizure phenotype if deletion
of GDH resulted in impaired glutamate uptake in vivo (42, 43).
Therefore, as has been observed with differential metabolism of
glutamate in different systems or with increased neuronal activity
[for reviews, see (44, 45)], it seems likely that redundant systems
may be differentially engaged to support glutamate uptake.
In the present study, we used crude membranes (P2). Previous
studies have demonstrated that the pharmacology of glutamate
uptake in cortical crude membranes parallels that observed for
GLT-1 and is distinct from that observed in cerebellar crude mem-
branes uptake (20, 24, 32). Furthermore, genetic deletion of GLT-1
reduces glutamate uptake in cortical crude membranes to 5% of
control (9). These studies provide compelling evidence that uptake
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measured in cortical crude membranes is mediated by GLT-1 and
that uptake measured in cerebellar crude membranes is mediated
by GLAST. We examined the abundance of a neuronal membrane
protein, the NR1 subunit of the NMDA receptor, and two glial
membrane proteins, GLT-1 and GLAST in this membrane prepa-
ration. As was previously observed (25, 26), we found that this
fraction contains high levels of neuronal and glial membrane pro-
teins. We also found low levels of the cytoskeletal proteins, GFAP
and NF-L. The absence of large amounts of either cytoskeletal
protein suggests that the membranes do not uniformly reseal into
vesicles and that the resealed vesicles contain only a small fraction
of the original cytosol. This conclusion is also supported by the
observation that cortical and cerebellar crude membranes contain
comparable levels of GLT-1 (Figure 1), even though no GLT-1-
mediated uptake is detected in cerebellar crude membranes (see
above).
GLT-1 expression, when analyzed using immunohistochemical
approaches (7, 15, 16), in situ hybridization of mRNA [(46, 47),
and for reviews, see (4, 5)], or bacterial artificial chromosome
GLT-1 promoter reporter mice (48), is essentially restricted to
astrocytes. However, there is also evidence that GLT-1 is expressed
in some neurons in the CNS (8, 47, 49). The P2 membrane prepa-
ration has also been used to examine the relative contributions
of the different GABA transporters to uptake. The pharmacology
of GABA transport in crude membranes (P2) is consistent with
GAT-1 (50, 51), which is thought to be localized predominantly
in neurons, but is also found in astrocytes [for review, see (52)].
Although GLT-1 is heavily enriched in astrocytes and GAT-1 is
enriched in neurons, it is not possible to determine if the effects
of inhibition of GDH are related to inhibition of neuronal or
glial pools of this enzyme. This will need to be a topic of further
investigation.
Glutamate dehydrogenase is a mitochondrial enzyme that cat-
alyzes the reversible deamination of glutamate to α-ketoglutarate
[for reviews, see (53, 54)]. This reaction is accompanied by the
production of NADH that can be used to generate ATP; the down-
stream metabolism of α-ketoglutarate through the tricarboxylic
acid cycle will also generate ATP. Cytoplasmic glutamate moves
into mitochondria by one of two different families of transporters;
neither of these processes transport d-aspartate (55, 56). Further-
more, GDH does not metabolize d-Asp (33). Therefore, although
it is theoretically possible that GDH might support inward trans-
port by rapidly metabolizing glutamate and thereby maintaining
a concentration gradient, this is unlikely because inhibition of
GDH also blocks transport of d-[3H]-Asp. Others have found
that synaptosomes enriched from P2 contain relatively high lev-
els of endogenous glutamate (57); therefore, it seems certain
that the crude membranes (P2) used in the present study con-
tain endogenous glutamate. Combined with the fact that these
inhibitors also block GABA transport, these observations sug-
gest that mitochondrial GDH provides energy for transport using
endogenous glutamate to drive the Na+-dependent transport
systems.
Several studies have demonstrated that inhibition of mitochon-
drial function impairs glutamate uptake. For example, the mito-
chondrial poisons, sodium azide, dinitrophenol, and antimycin
A, inhibit glutamate uptake in cultured astrocytes (58). In addi-
tion, MPP+ and rotenone, inhibitors of complex 1 of the electron
transport chain, inhibit glutamate clearance in both astrocytes
and crude cerebral synaptosomes (59, 60). Opening mitochon-
drial KATP channels can functionally support glutamate uptake in
the presence of MPP+ (61). There is also evidence that glutamate
transport couples to ionic changes in mitochondria. In fact, uptake
is accompanied by an increase in mitochondrial Na+ (62). Uptake
is also accompanied by acidification of mitochondria (63). This
may be dependent upon the mitochondrial glutamate–aspartate
exchanger, Aralar, which co-transports a H+ with glutamate (55),
or the mitochondrial glutamate carrier, which transports gluta-
mate with a H+ or in exchange for a hydroxyl ion (56). The
fact that inhibitors of GDH block glutamate uptake provides fur-
ther support for a functional interaction between transporters and
mitochondria.
Epigallocatechin-monogallate is considered the most active of
the green tea polyphenols, the likely active ingredients in green tea;
the effects of EGCG on biological/pathological processes have been
examined in numerous in vitro and in vivo studies. EGCG is of
particular interest in the treatment of Alzheimer’s and Parkinson’s
diseases because it exhibits neuroprotective effects such as radical
scavenging, iron chelating, activation of PKC, and anti-apoptotic
action [for review, see (64)]. In vivo studies have demonstrated the
neuroprotective properties of EGCG. For example, these polyphe-
nols improve spatial learning in aged rodents (65), they suppress
peripheral nerve degeneration associated with sciatic nerve crush
(66), and EGCG protects against hippocampal neuronal damage
after global ischemia (67). In vitro, EGCG is protective at low
concentrations, but at concentrations similar to those used in the
present study, EGCG causes cell death in a neuroblastoma cell line
(68). EGCG increases the amount of glutamate observed in the
effluent upon depolarization of synaptosomes (69). In pancreatic
β-cells, EGCG inhibits the increase in insulin secretion and gluta-
mine oxidation caused by the stimulation of GDH (21). In most
of these examples, it is unclear if the observed effects are related to
inhibition of GDH or to the anti-oxidant activity of EGCG. Inhi-
bition of GDH and glutamate uptake might contribute to some
of the observed in vivo effects, but this will need to be resolved in
future studies.
In summary, we show evidence that inhibition of the mitochon-
drial enzyme, GDH, can result in inhibition of Na+-dependent
l-glutamate or d-aspartate uptake in mammalian cortex. It seems
likely that this dependence on GDH is affected by factors that are
yet to be defined.
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